The ketogenic diet for the treatment of malignant glioma

Journal of Lipid Research

Volumn 56, Issue 1, 2015, Pages 5-10

  Woolf, Eric C ^a   Scheck, Adrienne C ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Brain tumor; Caloric restriction; Cancer; Glioblastoma multiforme; Glucose; Ketones; Metabolism; Therapy; Warburg effect

Indexed keywords

CALORIC RESTRICTION; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CARBOHYDRATE DIET; CLINICAL STUDY; GLIOBLASTOMA; HUMAN; KETOGENIC DIET; LIPID DIET; NONHUMAN; PROTEIN DIET; REVIEW; THERAPY EFFECT; TUMOR GROWTH; ANIMAL; BRAIN TUMOR; DIET THERAPY; GLIOMA; METABOLISM; PROCEDURES;

ANIMALS; BRAIN NEOPLASMS; CALORIC RESTRICTION; GLIOMA; HUMANS; KETOGENIC DIET;

EID: 84920507063     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R046797     Document Type: Review

References (80)

1. Bloch, O., S. J. Han, S. Cha, M. Z. Sun, M. K. Aghi, M. W. McDermott, M. S. Berger, and A. T. Parsa. 2012. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J. Neurosurg. 117: 1032-1038.
2. Anton, K., J. M. Baehring, and T. Mayer. 2012. Glioblastoma multiforme: overview of current treatment and future perspectives. Hematol. Oncol. Clin. North Am. 26: 825-853.
3. Weller, M., R. Stupp, M. Hegi, and W. Wick. 2012. Individualized targeted therapy for glioblastoma: fact or fiction? Cancer J. 18: 40-44.
4. The Cancer Genome Atlas Research Group. 2008. Comprehensive genomic characterization defi nes human glioblastoma genes and core pathways. Nature. 455: 1061-1068.
5. Brennan, C. 2011. Genomic profiles of glioma. Curr. Neurol. Neurosci. Rep. 11: 291-297.
6. Brennan, C., H. Momota, D. Hambardzumyan, T. Ozawa, A. Tandon, A. Pedraza, and E. Holland. 2009. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS ONE. 4: e7752.
7. Lee, Y., A. C. Scheck, T. F. Cloughesy, A. Lai, J. Dong, H. K. Farooqi, L. M. Liau, S. Horvath, P. S. Mischel, and S. F. Nelson. 2008. Gene expression analysis of glioblastomas identifi es the major molecular basis for the prognostic benefit of younger age. BMC Med. Genomics. 1: 52.
8. Verhaak, R. G., K. A. Hoadley, E. Purdom, V. Wang, Y. Qi, M. D. Wilkerson, C. R. Miller, L. Ding, T. Golub, J. P. Mesirov, et al. 2010. Integrated genomic analysis identifi es clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17: 98-110.
9. Masui, K., T. F. Cloughesy, and P. S. Mischel. 2012. Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol. Appl. Neurobiol. 38: 271-291.
10. Warburg, O. 1956. On the origin of cancer cells. Science. 123: 309-314.
11. Warburg, O., F. Wind, and E. Negelein. 1927. The metabolism of tumors in the body. J. Gen. Physiol. 8: 519-530.
12. Mischel, P. S. 2012. HOT models in fl ux: mitochondrial glucose oxidation fuels glioblastoma growth. Cell Metab. 15: 789-790.
13. Seyfried, T. N., M. A. Kiebish, J. Marsh, L. M. Shelton, L. C. Huysentruyt, and P. Mukherjee. 2011. Metabolic management of brain cancer. Biochim. Biophys. Acta. 1807: 577-594.
14. Wolf, A., S. Agnihotri, and A. Guha. 2010. Targeting metabolic remodeling in glioblastoma multiforme. Oncotarget. 1: 552-562.
15. Nijsten, M. W., and G. M. van Dam. 2009. Hypothesis: using the Warburg effect against cancer by reducing glucose and providing lactate. Med. Hypotheses. 73: 48-51.
16. Marie, S. K., and S. M. Shinjo. 2011. Metabolism and brain cancer. Clinics (Sao Paulo). 66 (Suppl 1): 33-43.
17. Puzio-Kuter, A. M. 2011. The role of p53 in metabolic regulation. Genes Cancer. 2: 385-391.
18. Robey, R. B., and N. Hay. 2009. Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin. Cancer Biol. 19: 25-31.
19. Yang, C., J. Sudderth, T. Dang, R. G. Bachoo, J. G. McDonald, and R. J. DeBerardinis. 2009. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 69: 7986-7993. [Erratum. 2010. Cancer Res. 70: 1275.]
20. Semenza, G. L. 2009. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin. Cancer Biol. 19: 12-16.
21. Yeung, S. J., J. Pan, and M. H. Lee. 2008. Roles of p53, MYC and HIF-1 in regulating glycolysis-the seventh hallmark of cancer. Cell. Mol. Life Sci. 65: 3981-3999.
22. Kim, Y., and J. M. Rho. 2008. The ketogenic diet and epilepsy. Curr. Opin. Clin. Nutr. Metab. Care. 11: 113-120.
23. Cross, J. H. 2013. New research with diets and epilepsy. J. Child Neurol. 28: 970-974.
24. Morris, A. A. M. 2005. Cerebral ketone body metabolism. J. Inherit. Metab. Dis. 28: 109-121.
25. Cahill, G. F., Jr., and R. L. Veech. 2003. Ketoacids? Good medicine? Trans. Am. Clin. Climatol. Assoc. 114: 149-161.
26. VanItallie, T. B., and T. H. Nufert. 2003. Ketones: metabolism's ugly duckling. Nutr. Rev. 61: 327-341.
27. Veech, R. L., B. Chance, Y. Kashiwaya, H. A. Lardy, and G. F. Cahill, Jr. 2001. Ketone bodies, potential therapeutic uses. IUBMB Life. 51: 241-247.
28. Stafstrom, C. E., and J. M. Rho. 2012. The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front. Pharmacol. 3: 59.
29. Maalouf, M., J. M. Rho, and M. P. Mattson. 2009. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res. Rev. 59: 293-315.
30. Maurer, G. D., D. P. Brucker, O. Bahr, P. N. Harter, E. Hattingen, S. Walenta, W. Mueller-Klieser, J. P. Steinbach, and J. Rieger. 2011. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer. 11: 315.
31. Zhou, W., P. Mukherjee, M. A. Kiebish, W. T. Markis, J. G. Mantis, and T. N. Seyfried. 2007. The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr. Metab. (Lond). 4: 5.
32. Seyfried, T. N., and P. Mukherjee. 2005. Targeting energy metabolism in brain cancer: review and hypothesis. Nutr. Metab. (Lond). 2: 30-38.
33. Tisdale, M. J., and R. A. Brennan. 1983. Loss of acetoacetate coenzyme A transferase activity in tumours of peripheral tissues. Br. J. Cancer. 47: 293-297.
34. Fredericks, M., and R. B. Ramsey. 1978. 3-Oxo acid coenzyme A transferase activity in brain and tumors of the nervous system. J. Neurochem. 31: 1529-1531.
35. Seyfried, T. N. 2012. Cancer as a Metabolic Disease: On the Origin, Management and Prevention of Cancer. John Wiley and Sons, Inc., Hoboken, NJ.
36. Magee, B. A., N. Potezny, A. M. Rofe, and R. A. Conyers. 1979. The inhibition of malignant cell growth by ketone bodies. Aust. J. Exp. Biol. Med. Sci. 57: 529-539.
37. Skinner, R., A. Trujillo, X. Ma, and E. A. Beierle. 2009. Ketone bodies inhibit the viability of human neuroblastoma cells. J. Pediatr. Surg. 44: 212-216.
38. Scheck, A. C., M. G. Abdelwahab, K. Fenton, and P. Stafford. 2012. The ketogenic diet for the treatment of glioma: insights from genetic profiling. Epilepsy Res. 100: 327-337.
39. Maalouf, M., P. G. Sullivan, L. Davis, D. Y. Kim, and J. M. Rho. 2007. Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation. Neuroscience. 145: 256-264.
40. Fruehauf, J. P., and F. L. Meyskens, Jr. 2007. Reactive oxygen species: a breath of life or death? Clin. Cancer Res. 13: 789-794.
41. Weinberg, F., and N. S. Chandel. 2009. Reactive oxygen species-dependent signaling regulates cancer. Cell. Mol. Life Sci. 66: 3663-3673.
42. Rous, P. 1914. The infl uence of diet on transplanted and spontaneous mouse tumors. J. Exp. Med. 20: 433-451.
43. Mukherjee, P., A. V. Sotnikov, H. J. Mangian, J. R. Zhou, W. J. Visek, and S. K. Clinton. 1999. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J. Natl. Cancer Inst. 91: 512-523.
44. De Lorenzo, M. S., E. Baljinnyam, D. E. Vatner, P. Abarzua, S. F. Vatner, and A. B. Rabson. 2011. Caloric restriction reduces growth of mammary tumors and metastases. Carcinogenesis. 32: 1381-1387.
45. Phoenix, K. N., F. Vumbaca, M. M. Fox, R. Evans, and K. P. Claffey. 2010. Dietary energy availability affects primary and metastatic breast cancer and metformin effi cacy. Breast Cancer Res. Treat. 123: 333-344.
46. Thompson, H. J., J. N. McGinley, N. S. Spoelstra, W. Jiang, Z. Zhu, and P. Wolfe. 2004. Effect of dietary energy restriction on vascular density during mammary carcinogenesis. Cancer Res. 64: 5643-5650.
47. Mukherjee, P., M. M. El-Abbadi, J. L. Kasperzyk, M. K. Ranes, and T. N. Seyfried. 2002. Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model. Br. J. Cancer. 86: 1615-1621.
48. Mukherjee, P., L. E. Abate, and T. N. Seyfried. 2004. Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin. Cancer Res. 10: 5622-5629.
49. Shelton, L. M., L. C. Huysentruyt, P. Mukherjee, and T. N. Seyfried. 2010. Calorie restriction as an anti-invasive therapy for malignant brain cancer in the VM mouse. ASN Neuro. 2: e00038.
50. Jiang, Y. S., and F. R. Wang. 2013. Caloric restriction reduces edema and prolongs survival in a mouse glioma model. J. Neurooncol. 114: 25-32.
51. Patel, M., M. A. Vogelbaum, G. H. Barnett, R. Jalali, and M. S. Ahluwalia. 2012. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. Expert Opin. Investig. Drugs. 21: 1247-1266.
52. El-Kenawi, A. E., and A. B. El-Remessy. 2013. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br. J. Pharmacol. 170: 712-729.
53. de Groot, J., D. A. Reardon, and T. T. Batchelor. 2013. Antiangiogenic therapy for glioblastoma. Am. Soc. Clin. Oncol. Educ. Book. 2013: 71-78.
54. Rutz, H. P., and I. Herr. 2005. Glucocorticoid administration in antiemetic therapy: is it safe? Cancer. 103: 2656-2657.
55. Mulrooney, T. J., J. Marsh, I. Urits, T. N. Seyfried, and P. Mukherjee. 2011. Infl uence of caloric restriction on constitutive expression of NF-κB in an experimental mouse astrocytoma. PLoS ONE. 6: e18085.
56. Urits, I., P. Mukherjee, J. Meidenbauer, and T. N. Seyfried. 2012. Dietary restriction promotes vessel maturation in a mouse astrocytoma. J. Oncol. 2012: 264039.
57. Stafford, P., M. G. Abdelwahab, D. Y. Kim, M. C. Preul, J. M. Rho, and A. C. Scheck. 2010. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr. Metab. (Lond). 7: 74.
58. Abdelwahab, M. G., K. E. Fenton, M. C. Preul, J. M. Rho, A. Lynch, P. Stafford, and A. C. Scheck. 2012. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS ONE. 7: e36197.
59. Woolf, E. C., P. Stafford, M. G. Abdelwahab, K. E. Fenton, M. C. Preul, and A. C. Scheck. 2013. The ketogenic diet potentiates radiation therapy in a mouse model of glioma: effects on inflammatory pathways and reactive oxygen species. (Abstract in Proceedings of the 104th Annual Meeting of the American Association for Cancer Research. Washington, DC, April 6-10, 2013). Cancer Res. 73 ( 8 Suppl 1): 4441.
60. Baylin, S. B., and P. A. Jones. 2011. A decade of exploring the cancer epigenome-biological and translational implications. Nat. Rev. Cancer. 11: 726-734.
61. Venneti, S., and C. B. Thompson. 2013. Metabolic modulation of epigenetics in gliomas. Brain Pathol. 23: 217-221.
62. Yun, J., J. L. Johnson, C. L. Hanigan, and J. W. Locasale. 2012. Interactions between epigenetics and metabolism in cancers. Front. Oncol. 2: 163.
63. Qureshi, I. A., and M. F. Mehler. 2013. Developing epigenetic diagnostics and therapeutics for brain disorders. Trends Mol. Med. 19: 732-741.
64. Azad, N., C. A. Zahnow, C. M. Rudin, and S. B. Baylin. 2013. The future of epigenetic therapy in solid tumours-lessons from the past. Nat. Rev. Clin. Oncol. 10: 256-266.
65. Shimazu, T., M. D. Hirschey, J. Newman, W. He, K. Shirakawa, M. N. Le, C. A. Grueter, H. Lim, L. R. Saunders, R. D. Stevens, et al. 2013. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 339: 211-214.
66. Kobow, K., A. Kaspi, K. N. Harikrishnan, K. Kiese, M. Ziemann, I. Khurana, I. Fritzsche, J. Hauke, E. Hahnen, R. Coras, et al. 2013. Deep sequencing reveals increased DNA methylation in chronic rat epilepsy. Acta Neuropathol. 126: 741-756.
67. Lee, C., L. Raffaghello, S. Brandhorst, F. M. Safdie, G. Bianchi, A. Martin-Montalvo, V. Pistoia, M. Wei, S. Hwang, A. Merlino, et al. 2012. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci. Transl. Med. 4: 124ra27.
68. Scheck, A. C., M. G. Abdelwahab, P. Stafford, D. Y. Kim, S. Iwai, M. C. Preul, and J. M. Rho. 2010. Mechanistic studies of the ketogenic diet as an adjuvant therapy for malignant gliomas. (Abstract in Proceedings: AACR 101st Annual Meeting 2010. Washington, DC, April 17-21, 2010). Cancer Res. 70 (8 Suppl): 638.
69. Allen, B. G., S. K. Bhatia, J. M. Buatti, K. E. Brandt, K. E. Lindholm, A. M. Button, L. I. Szweda, B. Smith, D. R. Spitz, and M. A. Fath. 2013. Ketogenic diets enhance oxidative stress and radio-chemotherapy responses in lung cancer xenografts. Clin. Cancer Res. 19: 3905-3913.
70. Raffaghello, L., C. Lee, F. M. Safdie, M. Wei, F. Madia, G. Bianchi, and V. D. Longo. 2008. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc. Natl. Acad. Sci. USA. 105: 8215-8220.
71. Lee, C., F. M. Safdie, L. Raffaghello, M. Wei, F. Madia, E. Parrella, D. Hwang, P. Cohen, G. Bianchi, and V. D. Longo. 2010. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res. 70: 1564-1572.
72. Seyfried, T. N., J. Marsh, L. M. Shelton, L. C. Huysentruyt, and P. Mukherjee. 2012. Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer? Epilepsy Res. 100: 310-326.
73. Safdie, F., S. Brandhorst, M. Wei, W. Wang, C. Lee, S. Hwang, P. S. Conti, T. C. Chen, and V. D. Longo. 2012. Fasting enhances the response of glioma to chemo- and radiotherapy. PLoS ONE. 7: e44603.
74. Marsh, J., P. Mukherjee, and T. N. Seyfried. 2008. Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the restricted ketogenic diet. Nutr. Metab. (Lond). 5: 33.
75. Aldea, M., C. Tomuleasa, B. Petrushev, S. Susman, G. I. Kacso, A. Irimie, I. S. Florian, and O. Soritau. 2011. Antidiabetic pharmacology: a link between metabolic syndrome and neuro-oncology? J. BUON. 16: 409-413.
76. Kohshi, K., T. Beppu, K. Tanaka, K. Ogawa, O. Inoue, I. Kukita, and R. E. Clarke. 2013. Potential roles of hyperbaric oxygenation in the treatments of brain tumors. Undersea Hyperb. Med. 40: 351-362.
77. Poff, A. M., C. Ari, T. N. Seyfried, and D. P. D'Agostino. 2013. The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. PLoS ONE. 8: e65522.
78. Nebeling, L. C., F. Miraldi, S. B. Shurin, and E. Lerner. 1995. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J. Am. Coll. Nutr. 14: 202-208.
79. Zuccoli, G., N. Marcello, A. Pisanello, F. Servadei, S. Vaccaro, P. Mukherjee, and T. N. Seyfried. 2010. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case report. Nutr. Metab. (Lond). 7: 33-53.
80. Schmidt, M., N. Pfetzer, M. Schwab, I. Strauss, and U. Kammerer. 2011. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial. Nutr. Metab. (Lond). 8: 54.